NicOx plans to get advice from a bank to fend off unsolicited takeover proposals as it holds discussions with drug companies interested in its naproxcinod, an experimental pain medication. The French biotech firm received more partnership offers after the release of trial results showing that naproxcinod causes fewer adverse reactions than naproxen, a common painkiller, CEO Michele Garufi said.

Full Story:

Related Summaries